Bayer AG Current Valuation vs. Book Value Per Share
| BAYN Stock | 18.94 0.07 0.37% |
For Bayer AG profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bayer AG to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bayer AG NA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bayer AG's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bayer AG NA over time as well as its relative position and ranking within its peers.
Bayer |
Bayer AG NA Book Value Per Share vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Bayer AG's current stock value. Our valuation model uses many indicators to compare Bayer AG value to that of its competitors to determine the firm's financial worth. Bayer AG NA is rated below average in current valuation category among its peers. It is rated third in book value per share category among its peers . The ratio of Current Valuation to Book Value Per Share for Bayer AG NA is about 1,973,939,527 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bayer AG's earnings, one of the primary drivers of an investment's value.Bayer Current Valuation vs. Competition
Bayer AG NA is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers-General industry is currently estimated at about 1.17 Trillion. Bayer AG holds roughly 82.93 Billion in current valuation claiming about 7% of equities under Drug Manufacturers-General industry.
Bayer Book Value Per Share vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Bayer AG |
| = | 82.93 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Bayer AG |
| = | 42.01 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Bayer Book Value Per Share Comparison
Bayer AG is rated second in book value per share category among its peers.
Bayer Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Bayer AG. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bayer AG position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bayer AG's important profitability drivers and their relationship over time.
Use Bayer AG in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bayer AG position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bayer AG will appreciate offsetting losses from the drop in the long position's value.Bayer AG Pair Trading
Bayer AG NA Pair Trading Analysis
The ability to find closely correlated positions to Bayer AG could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bayer AG when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bayer AG - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bayer AG NA to buy it.
The correlation of Bayer AG is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bayer AG moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bayer AG NA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bayer AG can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Bayer AG position
In addition to having Bayer AG in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run CNY Crypto Assets Thematic Idea Now
CNY Crypto Assets
An experimental p2p digital currency that is accepted by many vendors in Chinese Yuan. The CNY Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize CNY Crypto Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Bayer Stock
To fully project Bayer AG's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bayer AG NA at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bayer AG's income statement, its balance sheet, and the statement of cash flows.